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ManagementHeart failure (HF) biomarkers have dramatically impacted thewayHF patients are evaluated andmanaged. B-type
natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are the gold standard biomarkers in determining
the diagnosis and prognosis of HF, and studies on natriuretic peptide-guided HF management look promising. An
array of additional biomarkers has emerged, each reﬂecting different pathophysiological processes in the develop-
ment and progression of HF: myocardial insult, inﬂammation and remodeling. Novel biomarkers, such as
mid-regional pro atrial natriuretic peptide (MR-proANP),mid-regional pro adrenomedullin (MR-proADM), highly
sensitive troponins, soluble ST2 (sST2), growth differentiation factor (GDF)-15 and Galectin-3, show potential in
determining prognosis beyond the established natriuretic peptides, but their role in the clinical care of the patient
is still partially deﬁned and more studies are needed. This article is part of a Special Issue entitled: Heart failure
pathogenesis and emerging diagnostic and therapeutic interventions.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
A wide range of cardiovascular disorders that result in the impair-
ment of the heart's ability to ﬁll or to pump out blood may eventually
lead to the clinical syndrome of heart failure (HF). In recognition of
the multiplicity of causes of the diagnosis, it is not surprising that HF
is a common afﬂiction. Currently an estimated 5.8 million people in
the United States [1] and 23 million people worldwide [2] are living
with HF. As the population ages and treatments for cardiovascular
diseases are improving mortality in affected patients, the number of
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l rights reserved.Patients with HF often present with signs and symptoms that are
often nonspeciﬁc and with a wide differential diagnosis, making diagno-
sis by clinical presentation alone challenging. Some of the signs and
symptoms, such as dyspnea, orthopnea and paroxysmal nocturnal
dyspnea, are due to congestion while some are due to lack of adequate
cardiac output, including fatigue, weakness and exercise intolerance.
This heterogeneity of presentation often results in delays in deﬁnitive di-
agnosis and treatment, and such delays are linked with poor prognosis
[3]. Thus, together with HF's well-described risk for death and hospitali-
zation, the growing incidence and prevalence make it a priority.
The evaluation of a patient suspected of HFwas traditionally based on
clinical assessment with history, physical examination and chest x-ray.
However, in isolation, the performance of these methods of diagnosis
can be limited in accurately diagnosing HF. As a matter of fact, isolated
symptoms and signs correlate poorly with objective methods of cardiac
dysfunction [4–6]. One study looked at the relationship between three
clinical criteria that combined ﬁndings from history, physical examina-
tion and chest x-ray for the diagnosis of HF: the Framingham, the Duke
and the Boston criteria [7]. All of the clinical criteria were limited in sen-
sitivity (50–73%) and/or speciﬁcity (54–78%). Beyond clinical variables,
noninvasive imaging studies (such as echocardiography and radionu-
clide angiography) may be useful to identify or exclude HF. These
modalities can determine ventricular ejection fraction and diastolic dys-
function, as well as estimate chamber pressures. Echocardiograms can
also provide clues to the underlying etiology of HF and are an essential
part of assessment once the diagnosis is secured. However, many pa-
tients with abnormal ventricular systolic function on imaging studies
are asymptomatic and do not necessarily have the clinical syndrome of
HF [8,9]. For example, in one study of community-dwelling urban pa-
tients, 48% of patients with left ventricular ejection fraction ≤30% were
asymptomatic [8]. Echocardiograms are also costly and time consuming
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sive techniques such as bioelectrical impedance vector analysis estimate
body mass and water composition by bioelectrical impedance measure-
ments, resistance and reactance, andmay aid in the diagnosis of HF [10],
but suchmeasurements are cumbersome and are not speciﬁc to the diag-
nosis of HF, per se.
More invasive means such as right heart catheterization may be use-
ful to identify or exclude HF; indeed right heart catheterization is the
gold standard in determining cardiac output and chamber pressures
such as pulmonary capillary wedge pressure. However, as already artic-
ulated, many patients with abnormal cardiac output and chamber
pressures do not necessarily have the clinical syndrome of HF, while
many patients with HFmay have relatively normalmeasurements in be-
tween episodes of symptoms. Lastly, the risks of the nature of invasive
monitoringmake its role for routine diagnosis andmonitoring in HF lim-
ited [11].
Accordingly, the role of biomarkers to predict the onset of future HF,
to identify its presencewhen fully developed, to risk stratify affected pa-
tients, and possibly to serve as a biological tool to guide therapy for HF
has been recently examined.
Indeed, the introduction of objective, noninvasive, biologically
meaningful biomarkers to clinical assessment has considerably changed
the way HF is diagnosed and monitored. In this article, we will discuss
the role of established and novel biomarkers in HF.
2. Progression of HF and the biology of biomarkers
In the evolution of the heart froma) an at-risk but structurally normal
organ to b) cardiac insult and injury, to c) ventricular dysfunction, to d)
progression into symptomatic HF, it is nowknown that various remodel-
ing and neurohormonal activation pathways exist whose activitymay be
leveraged for biological monitoring. Indeed, along the complex path
from risk to fully developed HF, there are increasing numbers of injury,
remodeling and neurohormonal activation proteins discovered, whose
measurements might relay important information about HF (Table 1).
Some, such as B-type natriuretic peptide (BNP) and N-terminal proBNP
(NT-proBNP), are well validated and established in their use, while
some are still being explored for potential use in the clinical practice.
3. Natriuretic peptides
The natriuretic peptides represent the gold standard for biomarkers
in HF, and the understanding about their biology and their clinical use
have both grown exponentially since their introduction. Structurally
conserved across multiple species, a number of structurally similar
natriuretic peptides have been identiﬁed: atrial natriuretic peptide
(ANP), urodilantin (an isoform of ANP), B-type natriuretic peptide
(BNP), C-type natriuretic peptide and Dendroaspis natriuretic peptide
[12]. Of these, ANP and BNP are transcribed and primarily produced in
themyocytes of the atria and ventricles, respectively [13]; both are pro-
duced in response to myocardial stretch due to pressure or volumeTable 1
Biomarkers of heart failure.
Myocardial insult Neurohormonal activati
Myocyte stretch
• NT-proBNP, BNP, MR-proANP
Renin angiotensin syst
• Renin, angiotensin II, a
Myocardial Injury
• Troponin T, troponin I
Sympathetic nervous s
• Norepinephrine, Chrom
Oxidative stress
• Myeloperoxidase, oxidized low-density
lipoproteins, MR-proADM
Arginine vasopressin s
• Arginine vasopressin
BNP=B-type natriuretic peptide, GDF-15=growth differentiation factor-15, MR-proADM
peptide, NT-proBNP=N-terminal pro B-type natriuretic peptide.overload [14], conditions commonly found in HF. The biological func-
tions of ANP and BNP include various compensatory mechanisms such
as natriuresis, diuresis, and vasodilation [15,16].
3.1. Diagnosis of HF
BNP production in normal healthy individuals is minimal, with a
level of about 10 pg/mL [17]. In conditions of myocardial stretch, the in-
duction of the BNP gene results in the production and secretion of
prohormone proBNP1–108. This is cleaved into the biologically active
BNP1–32 (usually referred to as BNP) and biologically inert, but biochem-
ically more stable, NT-proBNP1–76 (usually referred to as NT-proBNP).
Both fragments plus the precursor, proBNP1–108, are detected in circula-
tion [18]. The majority of data regarding use of the B-type class has fo-
cused on measurement of either BNP or NT-proBNP.
The Breathing Not Properly Study [19] measured BNP levels in 1586
patients presenting to the emergency department with acute dyspnea.
Investigators found that patients with clinically diagnosed HF had
higher BNP levels compared with those without HF (mean 675±450
vs. 110±225 pg/mL, pb0.001). Increasing severity of HF, as measured
by New York Heart Association (NYHA) functional class, correlated di-
rectly with increasing concentrations of BNP (pb0.001). BNP was the
best single predictor of a ﬁnal diagnosis of HF compared with all indi-
vidual history, physical examination, chest x-ray and laboratory ﬁnd-
ings. The area under the curve (AUC) for BNP in receiver operating
characteristic curve testing was 0.91 (95 percent conﬁdence interval
[CI] 0.90 to 0.93; pb0.001) for the diagnosis of HF. A cutoff BNP value
of 100 pg/mL had a sensitivity of 90% and a speciﬁcity of 76%. In addi-
tion, BNP was more accurate (83%) than either The National Health
and Nutrition Examination Survey (NHANES) criteria (67%) or the Fra-
minghamcriteria (73%), two established sets of criteria for HFdiagnosis.
Importantly, the best method of diagnosis of HF was seen when BNP as
well as clinical ﬁndings were combined (Table 2).
NT-proBNP is cleared via different mechanisms and has a longer
half-life than BNP (70 minutes vs. 20 minutes), but it is believed to be
rather equivalent for diagnostic evaluation of patients with suspected
HF. The use of NT-proBNP in the diagnosis of acutely decompensated
HF was ﬁrst demonstrated in the ProBNP Investigation of Dyspnea in
the Emergency Department (PRIDE) Study [20], where NT-proBNP had
an AUC of 0.94 (pb .001) for the diagnosis of HF, again supplementing
clinical judgment as BNP did in the Breathing Not Properly study. Subse-
quently, the International Collaborative of NT-proBNP (ICON) study [21]
examined optimal applications of NT-proBNP in 1256 acutely dyspneic
patients. Patients with acutely decompensated HF had considerably
higher NT-proBNP concentrations, compared with those without HF
(4639 vs. 108 pg/mL, pb0.001); symptom severity correlated with
NT-proBNP concentrations (p=0.008). As natriuretic peptide concen-
trations rise with increasing age, the ICON investigators found the best
approach for use of NT-proBNP in HF diagnosis was through use of
age-stratiﬁed cutoff points; this approach improved the positive predic-
tive value of the assay considerably. Using the age stratiﬁed approachon Remodeling
em
ldosterone
Inﬂammation
• C-reactive protein, tumor necrosis factor α, Fas,
interleukins, osteoprotegerin, adiponectin
ystem
ogranin A
Hypertrophy/Fibrosis
• Matrix metalloproteinases, collagen propeptides,
galectin 3, soluble ST2
ystem Apoptosis
• GDF-15
=mid-regional pro adrenomedullin, MR-proANP=mid-regional pro atrial natriuretic
Table 2
Multiple logistic regression analysis of predictors of HF (Adapted with permission from
[19]).
Predictor Odds ratio (95% CI) p-Value
BNP>100 pg/mL 29.60 (17.75–49.37) b0.001
History of HF 11.08 (6.55–18.77) b0.001
Cephalization on chest x-ray 10.69 (5.32–21.47) b0.001
Edema 2.88 (1.81–4.57) b0.001
History of myocardial infarction 2.72 (1.63–4.54) b0.001
Rales 2.24 (1.41–3.58) b0.001
Jugular venous distention 1.87 (1.04–3.36) 0.04
Age (for each year of age) 1.02 (1.00–1.03) 0.04
BNP=B-type natriuretic peptide, HF=heart failure.
Fig. 1. Adjusted hazard ratio (HR) and 95% conﬁdence interval (CI) for clinical outcomes
by discharge B-type natriuretic peptide (BNP) (versus discharge BNP=300)—results
from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients
with Heart Failure (OPTIMIZE-HF) study. Though the focus of initial studies on BNP has
been on the predictive ability of baseline BNP values, OPTIMIZE-HF study demonstrates
that it was the ﬁnal achieved BNP concentrations after HF therapy that predicted future
outcomes well. Studies exploring BNP-guided HF management are based on this concept
of adjusting therapies to achieve a prognostically favorable “ﬁnal” biomarker concentra-
tion. Reproduced with permission from ref. [33].
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years or≥1800 pg/mL for age>75 years.), a sensitivity of 90% and spec-
iﬁcity of 84% for acute HF was found. In addition, the ICON investigators
found that very low concentrations of NT-proBNP were are particularly
handy in excluding HF, with excellent negative predictive value.
Much as in those with acute dyspnea presenting to the emergency
department, both BNP and NT-proBNP have been shown to be partic-
ularly useful in excluding HF in lesser acute settings such as primary
care setting [22].
As noted previously, HF is a heterogeneous group of syndromes that
manifest with a common set of symptoms and signs. About half of pa-
tients with HF have left ventricular systolic dysfunction (LVSD) and
the other half have HF with preserved left ventricular ejection fraction
(HFpEF) also known as diastolic HF. In recognition of their biologic trig-
ger for release (common to both types of HF), both BNP and NT-proBNP
are accurate for the diagnosis of HFwith LVSD or HFpEFwith good accu-
racy [23]. There may be slightly reduced sensitivity with HFpEF, due to
generally lower BNP or NT-proBNP values in these patients [24,25], but
the overall performance of the assays is acceptable.
The use of BNP and NT-proBNP for the diagnosis of HF has dramati-
cally impacted the standard of care in HF; all major societies including
the American College of Cardiology, the American Heart Association,
the Heart Failure Society of America and the European Society of Cardi-
ology recommend the use of BNP or NT-proBNP for the diagnosis of HF
in their clinical practice guidelines [11,26,27].
3.2. Prognosis
Across the wide stages of HF-from at-risk, apparently well patients
to those with end-stage HF, concentrations of BNP and NT-proBNP
have been found to be meaningful for predicting outcomes. This prog-
nostic value appears to be additive to other clinical factors, and at
least as strong as many of the novel biomarkers discussed below.
The literature on the value of BNP or NT-proBNP to predict adverse
outcomes is too large to summarize in one paragraph, but certain as-
pects are common to the studies examining both peptides in various
stages of HF.
In patients with acutely decompensatedHF, both BNP andNT-proBNP
were foundearly on to beof considerable signiﬁcance relative tohardout-
comes such as death or recurrent hospitalization. For example, in The
Acute Decompensated Heart Failure National Registry (ADHERE) registry
[28], among 48629 patients hospitalized with acutely decompensated HF
(due to eitherHFwith LVSD orHFpEF), therewas a linear relationship be-
tween increasing admission BNP and increasing in-hospital mortality,
even after adjusting for clinical and laboratory risk factors. Lending further
support, Doust and colleagues compiled results from 19 studies that
looked at the prognostic power of BNP for death or cardiovascular events
[29], and found that each 100 pg/mL increase in BNPwas associatedwith
a 35% increase in the relative risk of death (95% CI 22–49%, p=0.096).
Similarly, elevatedNT-proBNP values on acuteHF admissionwere predic-
tive of both intermediate (death at 76 days) [21] and long-termoutcomes
(with NT-proBNP values greater than 986 pg/mL predicting death at1 year) [30]. While these studies focused mainly on the baseline value
of either BNP or NT-proBNP for prognosis in acutely decompensated HF,
it appears that the ﬁnal, post-treatment concentration of either peptide
may be more prognostic than the baseline value (Fig. 1) [31–33]. This
has led to the natural question as to whether in-hospital monitoring of
either BNP or NT-proBNP would afford a better ability to identify higher
risk patients, with speciﬁc targeting of their therapy to reduce risk for
short and longer-term adverse outcome [34].
In chronic HF, both BNP and NT-proBNP were useful in determining
HF prognosis though NT-proBNP appeared to be slightly better at
predicting hospitalization [35]. Subsequent analyses from the same co-
hort [36] showed that serial measurement of BNP and NT-proBNP was
better at predicting mortality (median follow-up of 24.5 months) than
a single baseline measurement. Interestingly, NT-proBNP threshold
value of 1078 pg/mL, as determined by a univariate time-dependent re-
ceiver operator characteristic curve, was useful in further determining
prognosis by NT-proBNP categories.
Elevated BNP or NT-proBNP levels are also predictors of future HF
or other cardiovascular events in asymptomatic patients without
Table 3
Factors inﬂuencing the clinical interpretation of BNP or NT-proBNP values.
Factors that decrease BNP or NT-proBNP
• Obesity
Factors that increase BNP or NT-proBNP
Heart muscle disease
• Hypertrophic heart muscle diseases
• Inﬁltrative myocardiopathies, such as amyloidosis
• Acute cardiomyopathies, such as apical ballooning syndrome
• Inﬂammatory, including myocarditis and chemotherapy
• Coronary artery disease
Valvular heart disease
• Aortic stenosis and regurgitation
• Mitral stenosis and regurgitation
Arrhythmia
• Atrial ﬁbrillation and ﬂutter
Cardiotoxic drugs
• Anthracyclines and related compounds
Renal dysfunction
Anemia
Critical illness
• Bacterial sepsis
• Burns
• Adult respiratory distress syndrome
Stroke
Pulmonary heart disease
• Sleep apnea
• Pulmonary embolism
• Pulmonary hypertension
• Congenital heart disease
BNP=B-type natriuretic peptide, NT-proBNP=N-terminal pro B-type natriuretic
peptide.
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Heart Study without established HF [37] each standard deviation in-
crease of log-BNP levels (and similarly for NT-proBNP) was associated
with an adjusted increase in the risk of death (27%, p=0.009), ﬁrst
cardiovascular event (28%, p=0.03), new HF (77%, pb0.001), atrial ﬁ-
brillation (66%, pb0.001), and stroke or transient ischemic attack
(53%, p=0.002). Similarly, among patients with established structur-
al heart disease (such as those with chronic stable coronary disease),
concentrations of both BNP and NT-proBNP potently predicted onset
of future HF as well as death. Natriuretic peptide levels were not sig-
niﬁcantly related to the risk of coronary heart disease events, howev-
er [38,39].
Thus, as previously declared, BNP and NT-proBNP represent the
“gold standard” biomarker for prognosis against which other prog-
nostic biomarkers must be compared [40].
3.3. HF management
BNP and NT-proBNP concentrations typically fall with therapies
proven to improve mortality in HF such as drug therapy with beta
blockers [41], angiotensin converting enzyme inhibitors [42], angio-
tensin II receptor blockers [43] and aldosterone antagonists [44], as
well as following cardiac resynchronization therapy [45]. A decreas-
ing trend in natriuretic peptide levels portends a favorable prognosis
and meta-analysis showed substantial improvement in mortality
with HF management with a goal to reduce natriuretic peptide con-
centrations in addition to standard HF management [46]. Large ran-
domized multi-center trials are underway to better explore this
personalized, biologically driven approach to care.
3.4. Limitations of natriuretic peptide measurement
There are several important limitations to natriuretic peptides
that need to be kept in mind when interpreting their results. Concen-
trations of both are by no means 100% speciﬁc for the clinical diagno-
sis of “HF,” but elevated values for either biomarker usually identiﬁes
underlying structural heart disease as well as heightened risk.
Beyond advancing age and ventricular function as discussed
above, other factors inﬂuencing the clinical interpretation of BNP or
NT-proBNP values are listed in Table 3, and include obesity (which
lowers values through a suppression of BNP release), renal failure,
atrial arrhythmias, cardiotoxic agents, as well as structural heart dis-
ease beyond the clinical diagnosis of HF [47–49].
Speciﬁcally with respect to renal function, BNP and NT-proBNP are,
in part, passively excreted by the kidneys [50], which are responsible
for approximately 25% of the clearance of both peptides. Additionally,
as renal failure and HF have overlap in risk factors and epidemiology,
it is expected that worse renal function will be accompanied by worse
cardiac status. Thus, estimated glomerular ﬁltration rate is inversely re-
lated to the concentration of both BNP andNT-proBNP, and bothmaybe
signiﬁcantly elevated in those with renal failure even without obvious
clinical HF [51]; adjusted cutoff values have been proposed in renal in-
sufﬁciency for both.
3.5. Emerging natriuretic peptide assays: mid-regional pro atrial natriuretic
peptide (MR-proANP)
ANP production is increased in response to increased atrial wall
stretch in HF, but reliable detection of circulating ANP concentrations
can be challenging as its half-life is only 2–5 minutes [52]. The 126
amino acid prohormone of ANP, known as proANP, has a longer half-life
andmakes serummeasurement more feasible; a novel assay that detects
themid-regional zone of proANP (MR-proANP) is now available, and has
been evaluated as a test for HF.
In the Biomarkers in Acute Heart Failure (BACH) trial [53],
MR-proANP was measured in 1641 patients with acute dyspnea.Investigators of the study found that MR-proANP (cutoff point
≥120 pmol/L, sensitivity 97%, speciﬁcity 59.9%, accuracy 73.6%) was
noninferior to BNP (cutoff point ≥100 pg/mL, sensitivity 95.6%, spec-
iﬁcity 61.9%, accuracy 72.7%) in the diagnosis of acute HF and
appeared to improve diagnostic accuracy in the BNP grey zone (BNP
levels between 100 and 500 pg/mL) and in patients with obesity. In
the PRIDE study [54], MR-proANP was found to be an independent
predictor of HF diagnosis in a model that included NT-proBNP (odds
ratio=4.34, 95% CI=2.11–8.92, pb0.001), and correctly reclassiﬁed
both false negatives and false positives. These results suggest that
the combined use of MR-proANP and either BNP or NT-proBNP pro-
vides superior diagnostic accuracy than either alone.
Much as with either BNP or NT-proBNP, MR-proANP is prognostic
for adverse outcome in patients with acutely decompensated HF. In
the PRIDE study [54], elevated MR-proANP was independently prog-
nostic and reclassiﬁed mortality risk at 1 year (hazard ratio[HR]=
2.99, p=0.001) and at 4 years (HR=3.12, p=0.001). Kaplan–Meier
curves also showed that MR-proANP was associated with death out
to 4 years, by itself or with other biomarkers in a multimarker
strategy. In chronic HF, the Gruppo Italiano per lo Studio della
Sopravvivenza nell'Insufﬁcienza Cardiaca-Heart Failure (GISSI-HF) in-
vestigators [55] measured several biomarkers including MR-proANP
and NT-proBNP in 1237 stable patients and followed them for about
4 years. The prognostic accuracy for MR-proANP for mortality was
the best with an AUC of 0.74 (95%CI=0.71–0.77) with an optimal
cutoff point of 278 pmol/L, followed by NT-proBNP with an AUC
0.73 and an optimal cutoff of 1181 pg/mL (95% CI=0.70–0.76). In ad-
dition, MR-proANP added independent prognostic information be-
yond NT-proBNP and clinical risk factors in net reclassiﬁcation
analyses. Changes in MR-proANP over 3 months also appeared to be
predictive of future mortality.
3.6. Beyond natriuretic peptides in HF
Although the natriuretic peptides have revolutionized the use of
biological measures to evaluate, prognosticate, and possibly manage
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surement of other biomarkers reﬂecting relevant but independent
pathways may be useful.
As reviewed previously [56] and in Table 1, there is a very wide
range of possible biological measures to be considered in patients
with HF. However, many studies that have identiﬁed some of these
candidates have been somewhat limited in design or quality. Thus,
unless adhering to a strict set of criteria for evaluation (Table 4)
[57], it is difﬁcult to know what the many putative “next greatest”
biomarkers in HF add beyond the natriuretic peptides. In this regard,
we only consider those biomarkers that appear most promising for
use in HF; each of the following novel biomarkers was chosen for its
pathophysiologic tie to development and progression of HF as well
as studies demonstrating the link between the biomarker and clinical
diagnosis or outcomes beyond the information already provided by
the gold standard HF biomarkers, natriuretic peptides. Given the
proven diagnostic value of BNP and NT-proBNP, the focus for each
has been for prognostication, rather than diagnosis.4. Mid-regional pro adrenomedullin (MR-proADM)
Adrenomedullin (ADM) [58] was initially found in pheochromo-
cytoma cells in the adrenal medulla and has potent vasodilatory ef-
fects. Since then, ADM has been found in various organs including
the heart, where it appears to increased myocardial contractility
through a cyclic AMP-independent mechanism [58]. In addition, it ap-
pears to increase nitric oxide synthesis in conditions where cytokine
production is increased [59]. Circulating levels of ADM are elevated
in HF and correlate with decreasing left ventricular ejection fraction,
increasing pulmonary artery pressures and the presence of diastolic
dysfunction and restrictive ﬁlling patterns [60,61]. Infusion of ADM
in HF patients results in signiﬁcant vasodilation, increase in cardiac
index and reduction of pulmonary capillary wedge pressure [62].
Thus, ADM release appears to be a compensatory mechanism in HF.
While ADM itself is difﬁcult to measure, a commercial assay mea-
suring the mid-regional portion of the stable prohormone of ADM,
MR-proADM, has been developed and used to explore its role in HF.
In the BACH study [53], MR-proADM was powerfully prognostic for
death at 90 days, adding prognostic value beyond natriuretic pep-
tides. Subsequent data from the PRIDE study [54] solidiﬁed a potential
prognostic role for MR-proADM; among 560 patients MR-proADM
had the best AUC for mortality at 1 year. After 1 year, MR-proANP
and NT-proBNP had higher AUCs.
In chronic HF, MR-proADM appears to be similarly prognostic. The
Australia-New Zealand Heart Failure Study [63] was a randomized
trial of carvedilol in 297 patients with ischemic left ventricular dys-
function. Investigators measured MR-proADM before and after treat-
ment and found that above median levels of MR-proADM predicted
increased risk of mortality (risk ratio of 3.92, 95% CI=1.76–8.7) and
of HF hospitalization (risk ratio of 2.4, 95% CI=1.3–4.5) independent
of traditional clinical and echocardiographic factors. Treatment withTable 4
Criteria for evaluation of new biomarker [57].
Criteria
1. Thorough methods must be used, and the marker should be evaluated across a
wide range of patients using rigorous and contemporary statistical methods
2. Results should be easily obtained within a short period of time and provide
acceptable level of accuracy-deﬁned biological variation and low analytical
imprecision
3. Results should reﬂect important pathophysiological process in HF presence
and progression
4. Results should provide clinical useful information beyond status quo
HF=heart failure.carvedilol reduced the risk of death or HF hospitalization in patients
with above-median levels of NT-proBNP, MR-proADM or both.
While promising for predicting short-term prognosis, more data
are needed before MR-proADM is to be considered ready for prime
time clinical use. For example, considerable depth of understanding
regarding the clinical response to an elevatedMR-proADM is required
before testing would be justiﬁed.
4.1. Cardiac troponins
Cardiac troponins have traditionally been used for the diagnostic
evaluation for acute myocardial infarction (MI), but there are several
other disorders where cardiac troponins are elevated. One such disor-
der is HF [64]. The mechanisms of troponin release in HF are numer-
ous and include MI type 1, MI type 2 (in the presence or absence of
coronary artery disease respectively), as well as other non-coronary
causes, including cytotoxicity, apoptosis, and inﬂammation. Regard-
less of underlying etiologies of troponin elevation in patients with
HF, concentrations of the biomarker are strongly prognostic. With
the emergence of highly sensitive troponin (hsTn) assays, where
myocardial necrosis is now detected in a great majority of patients
with HF syndromes, the ability of the biomarker to provide prognostic
value is even more reﬁned.
In patients with acutely decompensated HF, Xue et al. [65] demon-
strated that concentrations of highly sensitive troponin I (hsTnI) were
frequently elevated, and typically more so in those patients destined
for a complication. Further, in serial measurements, hsTnI typically
rose (or remained elevated) in subjects with impending complica-
tions. In another analysis of patients with acutely decompensated
HF, Pascual-Figal and colleagues [66] combined results from testing
for highly sensitive troponin T (hsTnT) with NT-proBNP and soluble
ST2 (a biomarker discussed below), showing enhanced prognostic
value with the addition of each biomarker (Fig. 2). In a subsequent
analysis from this cohort, the investigators compared hsTnT with
conventional TnT, showing that the highly sensitive assay was partic-
ularly of prognostic value in those patients with undetectable con-
ventional TnT results [67].
Among those with chronic HF, similar hsTn results have been
reported. For example, in the Valsartan Heart Failure Trial (Val-HeFT)
[68] of 4053 chronic stable HF patients without overt evidence of
myocardial ischemia or infarction, detectable TnT (~10%, measured
with a conventional assay) was associated with an increased risk of
death (HR 2.08, 95% CI 1.72–2.52) and ﬁrst hospitalization for HF
(HR 1.55, 95% CI 1.25–1.93) at 2 years in Cox proportional hazards
models adjusted for clinical risk factors. Using the hsTnT method,
92% were found to have detectable myocardial necrosis, which pre-
dicted a linear increase in mortality in multivariable models (HR of
1.05, 95% CI=1.04–1.07, pb0.0001). Addition of hsTnT to models
adjusting for clinical risk factors as well as BNP improved prognostic
discrimination signiﬁcantly. In a larger study [69] combining patients
from the Val-HeFT study and the GISSI-HF study, an increasing hsTnT
concentration strongly predicted increased risk of mortality, but
modestly improved test performance beyond the information already
given by the baseline values. Of note, there was no signiﬁcant change
in hsTnT values between baseline and follow up values.
In at-risk subjects, such as older, community dwelling patients,
detection of hsTnT appears to predict future development of HF
(hsTnT >12.94 pg/mL had an incidence rate per 100 person-years
of 6.4 [95% CI=5.8–7.2]; adjusted HR 2.48 [95% CI=2.04–3.00])
and cardiovascular death (incidence rate per 100 person-years of
4.8 [95% CI=4.3–5.4]; adjusted HR 2.91 [95% CI=2.37–3.58]) [70].
In this population, hsTnT change >50% predicted incidence of HF
and cardiovascular death beyond baseline measures.
At present, while measurement of troponin is recommended to ex-
clude MI in patients presenting with acutely decompensated HF [71],
because of unclear therapeutic ramiﬁcations of the risk predicted by
Fig. 2. Kaplan–Meier survival curves according to the presence of none, one, two or all
three biomarkers—a multi-marker panel including soluble ST2, high-sensitivity troponin
T- and N-terminal pro-B-type natriuretic peptide (NT-proBNP), predictedworsening clin-
ical outcomes better than any single biomarker. Reproduced with permission from [66].
Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide:
complementary role for risk stratiﬁcation in acutely decompensated heart failure.
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non-acute settings remains only partially deﬁned.5. Soluble ST2 (sST2)
ST2 is a unique biomarker with pluripotent effects in vivo. ST2 is
believed to have immunomodulatory function as a cell-surface mark-
er of T helper type 2 lymphocytes and was initially described in the
context of cell proliferation, inﬂammatory states and autoimmune
diseases [72]. Importantly, however, the ST2 system is also strongly
induced in mechanical strain of cardiac ﬁbroblasts or cardiomyocytes
[73] and appears to be intimately involved in cardiac remodeling and
ﬁbrosis in HF. Through binding of its ligand (interleukin-33, which
has anti-ﬁbrosis and anti-remodeling effects) to either ST2 ligand
(ST2L) or a soluble “decoy receptor” version (sST2), the ST2 system
represents an inducible pathway participant in mitigation of biome-
chanical stress. Clinically, concentrations of sST2 are predicted by a
phenotype of cardiac decompensation and remodeling [74]. Com-
pared to other biomarkers, such as natriuretic peptides, advantages
of sST2 include that its concentration is not affected by age, renal
function or body mass index [75].
Prognostically speaking, sST2 represents a valid contender to be
added to the natriuretic peptides. Among 593 patients presenting
with acute dyspnea [76,77], there was a concentration-dependent re-
lationship between sST2 and many clinical markers of HF severity in-
cluding left ventricular ejection fraction and NYHA functional
classiﬁcation. An elevated sST2 was prognostic in both acutely
decompensated HF patients (HR=9.3, p=0.003) and in all dyspnea
patients (HR=5.6, pb0.001) in multivariable analyses and surpassed
NT-proBNP for predicting death; the AUC for predicting 1-year mor-
tality was 0.80 (pb0.001). In recognition of the independent
importance of NT-proBNP for prognosis, it is noteworthy that the
combination of a natriuretic peptide and sST2 was a stronger predic-
tor of death than either alone. Another study of patients with acutely
decompensated HF [78] found that a percent change in sST2 duringtreatment for acute HF was also predictive of 90-day mortality (AUC
0.783, pb0.001).
On the outpatient side, in an analysis of more than 1100 patients
with chronic HF [79], patientswith the highest decile of sST2 concentra-
tion had a HR of 3.2 (95% CI=2.2–4.7, pb0.0001) compared those with
the lowest decile of sST2. While the prognostic power of sST2 was sim-
ilar to that of NT-proBNP in this study, again, having both biomarkers
was the best strategy in determining prognosis. When sST2 and
NT-proBNPwere added to an established clinical risk model, the Seattle
heart failure model, 15% of subjects were reclassiﬁed (p=0.017).
With the developmentof a highly sensitive assay for itsmeasurement
[75], the potential utility of sST2 continues to grow, with emerging data
solidifying the potential role of sST2 across a broader demographic of pa-
tients. For example, among a normal population of subjects in the com-
munity [80], concentrations of the biomarker predicted future HF, even
when adjusted for other novel and established biomarkers and clinical
variables.
With preliminary data suggesting beneﬁt of therapies that miti-
gate ventricular remodeling among patients with elevated sST2 con-
centrations [81], the potential of its use to “guide” therapy for
prevention of HF complications appears promising.6. Growth differentiation factor (GDF)-15
GDF-15 is a member of the transforming growth factor-β cytokine
superfamily, and participates in mitigation of myocardial stress
and remodeling; expression of GDF-15 is strongly induced in
cardiomyocytes in response to metabolic stress such as cardiac ische-
mia (nitric oxide-dependent) or pressure overload state (angiotensin
2-dependent) [82–85]. Accordingly, GDF-15 is elevated in acute MI
and HF [86–88]. GDF-15 appears to be involved in the regulation of
cell differentiation and tissue repair with possible anti-apoptotic
and anti-hypertrophic effects and closely linked with tissue remodel-
ing [82,83].
Kempf and colleagues [86] measured circulating levels of GDF-15
in 455 chronic HF patients. About 75% of the study participants had
GDF-15 levels above the upper limit of normal, and increasing
GDF-15 concentration was associated with increasing symptom se-
verity of HF. When GDF-15 was divided into quartiles, higher values
were associated with increased risk of death during a follow up of
2 years (10.0%, 9.4%, 33.4% and 56.2% respectively, pb0.001). Even
after adjusting for various traditional risk factors that included
NT-proBNP, GDF-15 remained an independent predictor of mortality
(adjusted HR for 1 unit in the natural log scale 2.26, 95% CI 1.52–
3.37, pb0.001). Further data from 1734 patients from the Val-HeFT
study [89] lent support to the use of GDF-15 in this context. The bio-
marker was measured at baseline and after 12 months of treatment
with the angiotensin receptor blocker valsartan or placebo. Similar
to the study by Kempf and colleagues, the large majority of the pa-
tients (85%) had abnormal concentrations (>1200 ng/L). These high
levels were associated with features of advanced HF and other bio-
markers of neurohormonal activation, inﬂammation, myocyte injury
and renal dysfunction. In a multiple-variable Cox regression model
that included clinical risk factors, BNP, high-sensitivity C-reactive
protein and hsTnT, GDF-15 was an independent predictor of death
(HR 1.007, 95% CI 1.001–1.014). After randomization, over the ensu-
ing 12 months, GDF-15 levels increased (median increase 145 ng/L
in the placebo group and 173 ng/L in the valsartan group, p=0.94
for comparison between the groups) and such an increase was asso-
ciated with increased risk of death and ﬁrst morbid event even after
adjusting for other risk factors. Despite the link between GDF-15
and the angiotensin II receptor [90], no interaction between risk and
treatment with valsartan was observed [89]. Thus, much as with
many novel markers, the promise of therapy guidance using GDF-15
is not yet realized.
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Galectin-3 [91] is amacrophage productmember of the lectin family
and is found on a wide variety of cells and tissues surfaces. Its function
appears to be related to the inﬂammatory cascade following cardiac in-
jury, as well as pathways regulating cardiac contractility. It has a
number of biological roles, including and especially the formation of ﬁ-
brosis; in a pioneering study from the lab of Pinto [92], the galectin-3
gene was signiﬁcantly expressed in rat HF models, and with pericardial
instillation of galectin-3, considerable deposition of collagen was ob-
served. Further, other studies have shown that galectin-3 genetic
knockout mouse models are resistant to left ventricular pressure and
volume overload, with a slower progression to LV dysfunction or HF.
Clinically, galectin-3 was ﬁrst measured in subjects from the
PRIDE study [93]. Patients with HF had higher levels of galectin-3
compared with those without HF (median 9.2 ng/mL vs. 6.9 ng/mL,
pb0.001), but for the diagnosis of HF, NT-proBNP outperformed
galectin-3. On the other hand, galectin-3's ability to predict 60-day
mortality was superior to NT-proBNP even after adjusting for tradi-
tional risk factors. However, similar to previously discussed bio-
markers of prognosis, adding galectin-3 to NT-proBNP and other
risk factors provided the best strategy for predicting prognosis in HF.
In patients with chronic, ambulatory HF, concentrations of
galectin-3 were found to be prognostic [94–96]; interestingly, consis-
tent with the possibility that biomarkers of ﬁbrosis such as galectin-3
are particularly important in HFpEF (where diastolic non-compliance
is the primary mechanism of HF), de Boer and colleagues [97]
reported that galectin-3 was especially predictive of death in those
subjects with HF but without LVSD.
While therapy interactions with standard HFmedications are not yet
found for galectin-3, among a large cohort of participants with HF due to
LVSD in the Controlled Rosuvastatin Multinational Trial in Heart Failure
(CORONA) study [96], Gullestad and colleagues showed that lower
galectin-3 concentrations predicted response to therapywith cholesterol
lowering, suggesting that the biomarkermay beused to triage patients to
different therapy strategies; those with lower galectin-3, and hence like-
ly to survive their HF long enough for ischemic heart disease to become
relevant, would most beneﬁt from statin therapy.8. Conclusion
Traditional methods of assessment and management of HF are
limited by subjective interpretation, time consumption, cost or inva-
sive nature. Biomarkers theoretically offer convenient, objective,
safe and biologically relevant insight that complements clinical ﬁnd-
ings of the HF patient. Whether for determining diagnosis, prognosis,
or deciding on therapy choice, the ﬁeld of HF biomarkers is rich with
biomarkers reﬂective of different mechanism of HF development and
progression. With different biomarkers reﬂecting HF presence, the
various pathways involved in its progression, as well as identifying
unique therapy options for HF management, a multi-biomarker ap-
proach to the HF patient is not far ahead, allowing the unique oppor-
tunity for speciﬁcally tailoring care to the individual.References
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